85 The World Health Organisation (WHO) has introduced an updated classification for small round cell tumours, refining the understanding of conditions such as Ewing sarcoma and similar malignancies. These tumours, rare and often difficult to diagnose, have been a subject of continuous research due to their complex nature and overlapping characteristics with other types of cancers. The findings were published in the journal Human Pathology. The new classification is based on four main groups: Ewing sarcoma, round cell sarcoma with non-ETS fusions (such as NFATc2 and PATZ1), sarcoma with CIC rearranged genetic changes, and sarcoma with BCOR genetic changes. These changes come in response to advancements in molecular research and the discovery of specific genetic markers, which are increasingly being used to distinguish between different subtypes of small round cell sarcomas. Ewing sarcoma, the most common type among these tumours, primarily affects children and young adults. It typically arises in bones but can also occur in soft tissues. While its prognosis has improved over the years due to multimodal treatment options, it remains a highly aggressive cancer with a risk of metastasis at the time of diagnosis in about 25% of cases. A specific genetic fusion between the EWSR1 gene and an ETS family member, most frequently FLI1, results in the classic form of Ewing sarcoma. This genetic fusion is a key diagnostic marker and is typically confirmed through fluorescence in situ hybridisation (FISH) testing or next-generation sequencing. But the WHO report emphasises that not all Ewing sarcomas conform to this classic presentation. New variants, such as adamantinoma-like Ewing sarcoma, which affects the head and neck region, are increasingly recognised as distinct entities. These tumours exhibit different biological behaviour and epigenetic profiles compared to conventional Ewing sarcoma. A significant portion of the updated classification deals with sarcomas that were once thought to be similar to Ewing sarcoma but have now been reclassified as distinct conditions. These include round cell sarcomas with non-ETS fusions, such as those involving the NFATc2 and PATZ1 genes. These sarcomas share some clinical and histological features with Ewing sarcoma but differ significantly in their genetic makeup and behaviour. For instance, sarcomas with NFATc2 fusions tend to occur more frequently in bones, particularly in middle-aged men. Despite their resemblance to Ewing sarcoma, these tumours exhibit distinct molecular profiles, which are crucial for accurate diagnosis and treatment planning. The WHO classification highlights the importance of identifying such molecular distinctions, as they have implications for prognosis and treatment outcomes. CIC-rearranged sarcoma and sarcoma with BCOR genetic alterations are also part of the revised WHO classification. These cancers are now recognised as separate from Ewing sarcoma, although they share some overlapping features, such as CD99 positivity. CIC-rearranged sarcomas, in particular, tend to have a more aggressive clinical course, with a lower overall survival rate than Ewing sarcoma. Their rarity and the lack of specific treatment protocols further complicate the management of these patients. The reclassification aims to assist pathologists in making more accurate diagnoses, but it also underscores the complexities involved in distinguishing between these tumour types. Molecular testing, which was once considered an adjunct, has become a cornerstone of diagnosis. This shift reflects the growing recognition that genetic and molecular profiling are indispensable tools in modern oncology. These advancements in classification are not merely academic; they have real-world implications for patient care. By distinguishing between different types of small round cell sarcomas, oncologists can tailor treatment strategies more effectively. For example, tumours with CIC-rearrangements may not respond well to traditional chemotherapy regimens used for Ewing sarcoma, necessitating the exploration of alternative therapeutic options. While much progress has been made, the WHO report acknowledges that there are still gaps in understanding, particularly regarding the best treatment protocols for newly identified sarcoma subtypes. As research continues, these classifications are expected to evolve further, potentially leading to new treatment modalities that could improve survival rates for patients with these challenging cancers.